IPSEF - Crinetics Pharmaceuticals Begins IPO Process
Quick Take
Crinetics Pharmaceuticals (CRNX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
Crinetics is a clinical-stage pharmaceutical company that develops and manufactures pharmaceuticals for endocrine diseases and endocrine-related tumors.
CRNX has achieved promising Phase 1 trial results for its lead candidate for the treatment of acromegaly.
When we learn more details about valuation, I'll provide a final opinion.
Company And Technology
The San Diego, California-based firm was founded in 2008 to research, develop, and manufacture pharmaceuticals that affect peptide hormone receptors